Korean J Gastroenterol.  2019 Jan;73(1):16-18. 10.4166/kjg.2019.73.1.16.

A Review of the 2018 Asia-Pacific Working Group Consensus on Non-variceal Upper Gastrointestinal Bleeding

• Kim JS
• Kim BW

• KMID: 2432431
• DOI: http://doi.org/10.4166/kjg.2019.73.1.16

Abstract

Despite recent advances in endoscopic techniques and acid-suppressive therapies, non-variceal upper gastrointestinal bleeding (NVUGIB) is still associated with significant morbidity and mortality. The increased use of dual antiplatelet agents and oral anticoagulants has complicated the management of NVUGIB. Physicians often have to decide on when to discontinue and resume these medications in patients with NVUGIB. However, clinical data regarding the resumption of antiplatelets and anticoagulants are still minimal. Here, we report and summarize the key recommendations made in the recent Asia-Pacific guidelines regarding management of antithrombotics in patients with NVUGIB.

Keyword

Non-variceal upper gastrointestinal bleeding; Guideline; Platelet aggregation inhibitors; Anticoagulants

MeSH Terms

Anticoagulants
Consensus*
Hemorrhage*
Humans
Mortality
Platelet Aggregation Inhibitors
Anticoagulants
Platelet Aggregation Inhibitors

Reference

1. Hearnshaw SA, Logan RF, Lowe D, Travis SP, Murphy MF, Palmer KR. Acute upper gastrointestinal bleeding in the UK: patient characteristics, diagnoses and outcomes in the 2007 UK audit. Gut. 2011; 60:1327–1335.

2. Leontiadis GI, Molloy-Bland M, Moayyedi P, Howden CW. Effect of comorbidity on mortality in patients with peptic ulcer bleeding: systematic review and meta-analysis. Am J Gastroenterol. 2013; 108:331–345. quiz 346.

3. Targownik LE, Nabalamba A. Trends in management and outcomes of acute nonvariceal upper gastrointestinal bleeding: 1993–2003. Clin Gastroenterol Hepatol. 2006; 4:1459–1466.

4. Gralnek IM, Dumonceau JM, Kuipers EJ, et al. Diagnosis and management of nonvariceal upper gastrointestinal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) guideline. Endoscopy. 2015; 47:a1–a46.

5. Sung JJ, Chiu PC, Chan FKL, et al. Asia-Pacific working group consensus on non-variceal upper gastrointestinal bleeding: an update 2018. Gut. 2018; 67:1757–1768.

6. Furuta T, Sugimoto M, Kodaira C, et al. Influence of low-dose proton pump inhibitors administered concomitantly or separately on the anti-platelet function of clopidogrel. J Thromb Thrombolysis. 2017; 43:333–342.

7. Ohbuchi M, Noguchi K, Kawamura A, Usui T. Different effects of proton pump inhibitors and famotidine on the clopidogrel metabolic activation by recombinant CYP2B6, CYP2C19 and CYP3A4. Xenobiotica. 2012; 42:633–640.

8. Zvyaga T, Chang SY, Chen C, et al. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19. Drug Metab Dispos. 2012; 40:1698–1711.

9. Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010; 363:1909–1917.

10. Sung JJ, Lau JY, Ching JY, et al. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann Intern Med. 2010; 152:1–9.

11. Derogar M, Sandblom G, Lundell L, et al. Discontinuation of low-dose aspirin therapy after peptic ulcer bleeding increases risk of death and acute cardiovascular events. Clin Gastroenterol Hepatol. 2013; 11:38–42.

12. Abraham NS, Hartman C, Richardson P, Castillo D, Street RL Jr, Naik AD. Risk of lower and upper gastrointestinal bleeding, transfusions, and hospitalizations with complex antithrombotic therapy in elderly patients. Circulation. 2013; 128:1869–1877.

13. Eisenberg MJ, Richard PR, Libersan D, Filion KB. Safety of short-term discontinuation of antiplatelet therapy in patients with drug-eluting stents. Circulation. 2009; 119:1634–1642.

14. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the national registry of atrial fibrillation. JAMA. 2001; 285:2864–2870.

15. Lip GY, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR, elderly, drugs/alcohol concomitantly) score. J Am Coll Cardiol. 2011; 57:173–180.